New gluten challenge study aims to make 'Gluten-Free' labels safer

NCT ID NCT06151782

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This completed study from Oslo University Hospital involved 33 adults with celiac disease who followed a strict gluten-free diet. Over five separate one-day challenges, participants consumed wheat gluten, barley gluten, hydrolyzed barley gluten, or a placebo. Researchers measured immune responses in the blood and gluten fragments in urine and stool to see which forms of gluten trigger reactions. The goal was to develop better analytical methods to assess the safety of partially hydrolyzed gluten in food products for celiac patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
gluten (wheat and barley, including hydrolyzed barley)
What this could lead to
If successful, this could lead to better methods for testing whether processed gluten-containing ingredients are safe for people with celiac disease.
What could go wrong
This was a small, early-stage study with only 33 participants, and the results may not apply to all celiac patients or all gluten-containing products.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CELIAC DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

celiac disease Food Intolerance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Clinical Center for Celiac Disease and Autoimmunity

    Mainz, Germany, 55131, Germany

  • Dept of Gastroenterology

    Oslo, Oslo, 0881, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.